Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 2/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 6/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.41 |
| ▸ | ATR | Q13535 | 2/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.37 |
| ▸ | NNMT | P40261 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17469783 | 0.87 | FLT3 (0.52) | FLT3GRM5 | |
| SCHEMBL17469805 | 0.85 | FLT3 (0.71) | FLT3GRM5 | |
| SCHEMBL7258784 | 0.83 | FLT3 (0.45) | FLT3GRM5SMN1; SMN2 | |
| SCHEMBL21103785 | 0.83 | FLT3 (0.76) | FLT3GRM5CHEK2MKNK1MKNK2 | |
| SCHEMBL17459806 | 0.81 | FLT3 (0.47) | FLT3ATR | |
| SCHEMBL19006332 | 0.78 | FLT3 (0.43) | FLT3 | |
| SCHEMBL19891381 | 0.75 | PIK3CA (0.43) | FLT3GRM5 | |
| SCHEMBL23599995 | 0.74 | ATR (0.48) | ATRSMN1; SMN2 | |
| SCHEMBL19891424 | 0.74 | PIK3CA (0.37) | FLT3GRM5 | |
| SCHEMBL21152882 | 0.73 | FLT3 (0.39) | FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198208-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | PURDUE RESEARCH FOUNDATION (US) | 2021-07-01 | — | — | US | disclosed |
| US-20190209548-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, BALTIMORE | 2019-07-11 | — | — | US | disclosed |
| US-20170174620-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2017-06-22 | — | — | US | disclosed |
| US-20170174620-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2017-06-22 | — | — | US | disclosed |
| WO-2016014674-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174620-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | MCL1, DPYD, TOP2B | FLT3 2354/4885GRM5 4401/4885CHEK2 145/4885 |
| US-20210198208-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | MCL1, ABL1, FLT3 | FLT3 3/4885GRM5 755/4885CHEK2 563/4885 |
| US-20190209548-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | MCL1, DPYD, TOP2B | FLT3 2354/4885GRM5 4401/4885CHEK2 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.